touchPODCAST

Exploring all angles: Neuroprotective strategies beyond IOP in primary and steroid-induced open-angle glaucoma

touchEXPERT FOCUS for touchOPHTHALMOLOGY

 

Listen to a series of interviews with Dr Maria-João Menéres who will provide her expert insights into the mechanisms of retinal ganglion cell (RGC) damage in both primary open-angle and secondary, steroid-induced glaucoma, and the importance of neuroprotection to mitigate the risk of glaucoma development or progression.

The expert:

• Dr Maria-João Menéres, ULS Santo António, Porto, Portugal

This touchPODCAST is for HCPs in Portugal only.

This activity is funded by an independent medical education grant from Alimera Sciences Europe Limited.

The activity is provided by touchIME.
touchIME is an EBAC® accredited provider.

For further information visit our website: www.touchOPHTHALMOLOGY.com   

Optimizing presbyopia-correcting IOL selection and patient expectations

touchEXPERT FOCUS for touchOPHTHALMOLOGY

Listen as Prof. Sumit (Sam) Garg shares expert clinical insights on how AI-supported biometric analysis can increase refractive accuracy and support confident presbyopia-correcting IOL selection, including which patient and ocular characteristics are most likely to benefit from AI-based tools. He also outlines practical strategies for structuring preoperative counselling to set realistic expectations and improve patient satisfaction through clear, effective communication.

 

The expert:

• Prof. Sumit (Sam) Garg, University of California, Irvine, CA, USA

This touchPODCAST is for HCPs outside of the UK.

This educational activity is funded by an independent medical education grant from Johnson & Johnson Surgical Vision, Inc.

This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

 

For further information visit our website: 

https://touchophthalmology.org

Advancing outcomes in CP-CML: Guideline-directed approaches to treatment decision-making, monitoring and toxicity management

touchPANEL DISCUSSION for touchHAEMATOLOGY and touchONCOLOGY

Listen to leading experts discuss guideline-directed strategies for mutational analysis and monitoring response when treating patients with chronic-phase chronic myeloid leukaemia with approved tyrosine kinase inhibitors.

The experts

• Dr Jorge Cortes, Georgia Cancer Center, Augusta, GA, USA
• Dr Elias Jabbour, MD Anderson Cancer Center, Houston, TX, USA 
• Dr Vivian Oehler, Fred Hutch Cancer Center, Seattle, WA, USA

This touchPODCAST is for HCPs in the USA only.

This activity is funded by an independent medical education grant from Takeda Development Center Americas, Inc.

Jointly provided by Partners for Advancing Clinical Education and touchIME.

For further information, visit our websites: 
www.touchHAEMATOLOGY.com
www.touchONCOLOGY.com

The bare necessities of hyperphagia in Prader–Willi syndrome: Expert insights on recognition and management

touchEXPERT FOCUS for touchENDOCRINOLOGY

Listen to a series of short interviews with paediatric endocrinologist Dr Ashley Shoemaker as she discusses the clinical manifestations and pathophysiology of Prader–Willi syndrome (PWS), with a focus on hyperphagia by exploring the spectrum across the lifespan of PWS and shares best practices for managing PWS-related hyperphagia within a multidisciplinary framework.

The expert:

• Dr Ashley Shoemaker, Vanderbilt University Medical Center, Nashville, TN, USA

This touchPODCAST is for HCPs in the USA only.

This activity is funded by an independent medical education grant from Soleno Therapeutics.

The activity is jointly provided by Partners for Advancing Clinical Education (Partners) and touchIME.

 

For further information, visit our website: https://touchendocrinologyime.org/hyperphagia-pws-recognition-management/

Targeting brain metastases in advanced NSCLC: The emerging impact of ADCs

touchPANEL DISCUSSION for touchONCOLOGY and touchRESPIRATORY

 

Listen to leading experts discuss the role of antibody–drug conjugates (ADCs) in NSCLC with brain metastases, including the latest clinical trial evidence, practical approaches to patient selection and treatment sequencing alongside local CNS therapies, and the evolving pipeline of investigational ADCs.

The expert(s)

• Dr Lyudmila Bazhenova, Moore’s Cancer Center, San Diego, CA, USA
• Dr Elvire Pons-Tostivint, Nantes Université, Centre Hospitalier Universitaire Nantes, France
• Dr Julia Rotow, Dana-Farber Cancer Institute, Boston, MA, USA

This touchPODCAST is for HCPs only outside of the UK.

This activity is funded by an independent medical education grant fromAstraZeneca.

This activity is jointly provided by USF Health and touchIME. 
touchIME is an EBAC® accredited provider.

For further information visit our websites: 

www.touchONCOLOGY.com
www.touchRESPIRATORY.com

Evolving paradigms in PNH management: Interpreting the latest data

touchPANEL DISCUSSION for touchHAEMATOLOGY and touchONCOLOGY

Listen to a panel of leading experts as they explore the latest advances in PNH pathophysiology, diagnostic approaches and therapeutic strategies, including data from ASH 2025, with practical insights for contemporary clinical practice.

The experts:

• Prof. Bruno Fattizzo, Università degli Studi di Milano, Milan, Italy
• Dr Austin Kulasekararaj, King’s College Hospital NHS Foundation Trust, London, UK
• Dr Srikanth Nagalla, Miami Cancer Institute, Miami, FL, USA

This touchPODCAST is for HCPs outside of the UK.

This activity is funded by an independent medical education grant from Alexion Pharma GmbH.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: www.touchHAEMATOLOGY.com or www.touchONCOLOGY.com

Diagnosis, multidisciplinary monitoring and individualized management in LOPD

touchCASES for touchNEUROLOGY, touchCARDIO, touchENDOCRINOLOGY and touchRESPIRATORY

Listen to two experts as they discuss three cases illustrating the heterogeneous, multisystem nature of late-onset Pompe disease (LOPD). They examine key decision points from recognizing early clinical clues and confirming diagnosis to optimizing enzyme replacement therapy (ERT), monitoring progression and coordinating multidisciplinary, patient-centred care. 

The experts:

• Prof. John Vissing, University of Copenhagen, Copenhagen, Denmark
• Prof. Pascal Laforêt, Versailles-Saint Quentin University, Versailles, France 

This activity is for HCPs outside of the USA.

This activity is supported by an independent educational grant from Amicus Therapeutics UK LTD.

touchIME is an EBAC® accredited provider.

For further information visit our websites: 

touchNEUROLOGY -  https://touchneurologyime.org/diagnosis-monitoring-management-lopd/
touchCARDIO - https://touchcardioime.org/diagnosis-monitoring-management-lopd/
touchENDOCRINOLOGY - https://touchendocrinologyime.org/diagnosis-monitoring-management-lopd/
touchRESPIRATORY - https://touchrespiratoryime.org/diagnosis-monitoring-management-lopd/

 

Unlocking the possibilities of BCMA-directed therapies in RRMM: Latest perspectives from IMS and ASH 2025

touchCONGRESS for touchHAEMATOLOGY and touchONCOLOGY

Listen to multiple myeloma expert Dr Rakesh Popat review key data for BCMA-targeting agents in the treatment of relapsed/refractory multiple myeloma presented at the International Multiple Society (IMS) and American Society of Hematology (ASH) 2025 congresses. Dr Popat is then joined by fellow experts Dr Paula Rodríguez-Otero and Dr Roberto Mina to discuss the implications of these data for current and future clinical practice.

 

Overview

• Data reviews with Dr Popat
• Expert panel discussions with Dr Popat, Dr Rodríguez-Otero and Dr Mina on the themes below

Clinical themes

• Approved BCMA-directed therapeutic approaches 
• Practical application of BCMA-directed therapies
• Future of treating RRMM: Emerging BCMA-directed therapies and combinations

The internationally renowned multiple myeloma expert faculty

• Dr Rakesh Popat: London, UK

• Dr Paula Rodríguez-Otero: Pamplona, Spain
• Dr Roberto Mina: Atlanta, GA, USA

This touchPODCAST is for HCPs outside of the USA. 

This activity is funded by an independent medical education grant from GSK.

This activity is provided by touchIME.
touchIME is an EBAC® accredited provider.

For further information, visit our website: www.touchHAEMATOLOGY.com and www.touchONCOLOGY.com

Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC

touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY

Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms

In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients.

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Prof. Nicholas Girard, Institut Curie, Paris, France

 

Module 2: Bridging resistance gaps post–EGFR-TKI: Expanding NSCLC treatment beyond actionable targets

In this module, Professor Pasi Jänne and Dr. Helena Yu discuss the evolving management of EGFR-mutant NSCLC after EGFR-TKI progression. They address challenges of unexplained resistance, review combination and ADC treatment approaches, and highlight key factors such as patient selection, safety and emerging biomarkers

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Dr Helena Yu, Memorial Sloan Kettering Cancer Center, New York, NY, USA

 

Module 3: Targeting resistance in EGFR-mutant NSCLC: The role of biomarkers

In this module, Professor Pasi Jänne and Professor Paul Hofman explore how precision medicine and molecular resistance mechanisms are shaping testing strategies. They discuss the role of biomarkers, evolving guideline recommendations and how clinicians can adapt testing approaches to align with new targeted therapies.

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Prof. Paul Hofman, University Côte d’Azur, Nice, France.

 

 

This touchPODCAST is for HCPs only.

This activity is funded by an educational grant from AstraZeneca Ltd. 

This medical education is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website:  

https://touchoncologyime.org/egfr-tki-resistance-strategies-nsclc/

https://touchrespiratoryime.org/egfr-tki-resistance-strategies-nsclc/

 

Evolving strategies in low-grade serous ovarian cancer: Applying the evidence to optimize patient care

touchEXPERT FOCUS for touchONCOLOGY

Listen to insights from Dr Kathleen Moore on the pathophysiology and molecular features of low-grade serous ovarian cancer (LGSOC) and how it differs from other ovarian cancers. She also discusses evidence-based treatment options and sequencing, as well as practical considerations relating to administration and side-effect management.

The expert:

• Dr Kathleen Moore, OH Health Stephenson Cancer Center, Oklahoma City, OK, USA
  

This touchPODCAST is for HCPs in the USA only.

This activity is funded by an independent medical education grant from Verastem, Inc.

The activity is jointly provided by Partners for Advancing Clinical Education and touchIME.

For further information visit our website: www.touchONCOLOGY.com